Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

November 01, 1996; Volume 50,Issue 5
  • You have access
    Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
    D Arion, R S Fletcher, G Borkow, M J Camarasa, J Balzarini, G I Dmitrienko and M A Parniak
    Molecular Pharmacology November 1996, 50 (5) 1057-1064;
  • You have access
    Induction of cytochrome P450 2E1 expression in rat and gerbil astrocytes by inflammatory factors and ischemic injury.
    N Tindberg, H A Baldwin, A J Cross and M Ingelman-Sundberg
    Molecular Pharmacology November 1996, 50 (5) 1065-1072;
  • You have access
    Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    M Morissette, M Goulet, F Calon, P Falardeau, P J Blanchet, P J Bédard and T Di Paolo
    Molecular Pharmacology November 1996, 50 (5) 1073-1079;
  • You have access
    Isolation and characterization of a cisplatin-resistant strain of Schizosaccharomyces pombe.
    P Perego, G Jimenez and S B Howell
    Molecular Pharmacology November 1996, 50 (5) 1080-1086;
  • You have access
    Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells.
    J M Gimble, C E Robinson, X Wu, K A Kelly, B R Rodriguez, S A Kliewer, J M Lehmann and D C Morris
    Molecular Pharmacology November 1996, 50 (5) 1087-1094;
  • You have access
    Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA.
    J L Nitiss and J C Wang
    Molecular Pharmacology November 1996, 50 (5) 1095-1102;
  • You have access
    Differential regulation of corticotropin-releasing factor1 receptor expression by stress and agonist treatments in brain and cultured cells.
    P A Iredale, R Terwilliger, K L Widnell, E J Nestler and R S Duman
    Molecular Pharmacology November 1996, 50 (5) 1103-1110;
  • You have access
    CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance.
    D C Zeldin, J Foley, J Ma, J E Boyle, J M Pascual, C R Moomaw, K B Tomer, C Steenbergen and S Wu
    Molecular Pharmacology November 1996, 50 (5) 1111-1117;
  • You have access
    Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding.
    M M Zhao, J Hwa and D M Perez
    Molecular Pharmacology November 1996, 50 (5) 1118-1126;
  • You have access
    Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages.
    K S Selander, J Mönkkönen, E K Karhukorpi, P Härkönen, R Hannuniemi and H K Väänänen
    Molecular Pharmacology November 1996, 50 (5) 1127-1138;
  • You have access
    Involvement of mitogen-activated protein kinase and translocation of cytosolic phospholipase A2 to the nuclear envelope in acetylcholine-induced prostacyclin synthesis in rabbit coronary endothelial cells.
    H Kan, Y Ruan and K U Malik
    Molecular Pharmacology November 1996, 50 (5) 1139-1147;
  • You have access
    Feminization of hepatic cytochrome P450s by nominal levels of growth hormone in the feminine plasma profile.
    N A Pampori and B H Shapiro
    Molecular Pharmacology November 1996, 50 (5) 1148-1156;
  • You have access
    Rat 17 beta-hydroxysteroid dehydrogenase type IV is a novel peroxisome proliferator-inducible gene.
    J C Corton, C Bocos, E S Moreno, A Merritt, D S Marsman, P J Sausen, R C Cattley and J A Gustafsson
    Molecular Pharmacology November 1996, 50 (5) 1157-1166;
  • You have access
    Three new toxins from the scorpion Pandinus imperator selectively block certain voltage-gated K+ channels.
    R S Rogowski, J H Collins, T J O'Neill, T A Gustafson, T R Werkman, M A Rogawski, T C Tenenholz, D J Weber and M P Blaustein
    Molecular Pharmacology November 1996, 50 (5) 1167-1177;
  • You have access
    Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells.
    J W Lawrence, D C Claire, V Weissig and T C Rowe
    Molecular Pharmacology November 1996, 50 (5) 1178-1188;
  • You have access
    The neurokinin-1 receptor antagonist LY306,740 blocks nociception-induced increases in dorsal horn neurokinin-1 receptor gene expression.
    K E McCarson and J E Krause
    Molecular Pharmacology November 1996, 50 (5) 1189-1199;
  • You have access
    Novel antagonists of the inhibitory glycine receptor derived from quinolinic acid compounds.
    V Schmieden, S Jezequel and H Betz
    Molecular Pharmacology November 1996, 50 (5) 1200-1206;
  • You have access
    Antiretrovirus specificity and intracellular metabolism of 2',3' -didehydro-2',3'-dideoxythymidine (stavudine) and its 5'-monophosphate triester prodrug So324.
    J Balzarini, H Egberink, K Hartmann, D Cahard, T Vahlenkamp, H Thormar, E De Clercq and C McGuigan
    Molecular Pharmacology November 1996, 50 (5) 1207-1213;
  • You have access
    Agonist-induced functional desensitization of the mu-opioid receptor is mediated by loss of membrane receptors rather than uncoupling from G protein.
    Y Pak, A Kouvelas, M A Scheideler, J Rasmussen, B F O'Dowd and S R George
    Molecular Pharmacology November 1996, 50 (5) 1214-1222;
  • You have access
    Enantiomers of myo-inositol-1,3,4-trisphosphate and myo-inositol-1,4,6 -trisphosphate: stereospecific recognition by cerebellar and platelet myo-inositol-1,4,5-trisphosphate receptors.
    C T Murphy, A J Bullock, C J Lindley, S J Mills, A M Riley, B V Potter and J Westwick
    Molecular Pharmacology November 1996, 50 (5) 1223-1230;
  • You have access
    Evidence for distinction of the differentiation-inducing activities and cytostatic properties of 9-(2-phosphonylmethoxyethyl)adenine and a variety of differentiation-inducing agents in human erythroleukemia K562 cells.
    S Hatse, E De Clercq and J Balzarini
    Molecular Pharmacology November 1996, 50 (5) 1231-1242;
  • You have access
    Pharmacological differentiation between intracellular calcium pump isoforms.
    S Engelender and L De Meis
    Molecular Pharmacology November 1996, 50 (5) 1243-1252;
  • You have access
    Pharmacological modulation of the diazepam-insensitive recombinant gamma-aminobutyric acidA receptors alpha 4 beta 2 gamma 2 and alpha 6 beta 2 gamma 2.
    F Knoflach, D Benke, Y Wang, L Scheurer, H Lüddens, B J Hamilton, D B Carter, H Mohler and J A Benson
    Molecular Pharmacology November 1996, 50 (5) 1253-1261;
  • You have access
    Cyclic AMP-independent inhibition of cardiac calcium current by forskolin.
    T Asai, S Pelzer and T F McDonald
    Molecular Pharmacology November 1996, 50 (5) 1262-1272;
  • You have access
    Membrane-delimited G protein-mediated coupling between V1a vasopressin receptor and dihydropyridine binding sites in rat glomerulosa cells.
    E Grazzini, T Durroux, M D Payet, L Bilodeau, N Gallo-Payet and G Guillon
    Molecular Pharmacology November 1996, 50 (5) 1273-1283;
  • You have access
    Direct inhibition of 5-hydroxytryptamine3 receptors by antagonists of L-type Ca2+ channels.
    A C Hargreaves, M J Gunthorpe, C W Taylor and S C Lummis
    Molecular Pharmacology November 1996, 50 (5) 1284-1294;
  • You have access
    Regulation of D2 dopamine receptors by amiloride and amiloride analogs.
    S R Hoare and P G Strange
    Molecular Pharmacology November 1996, 50 (5) 1295-1308;
  • You have access
    Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system.
    J M Masserano, L Gong, H Kulaga, I Baker and R J Wyatt
    Molecular Pharmacology November 1996, 50 (5) 1309-1315;
  • You have access
    5-Hydroxytryptamine4 receptors reduce afterhyperpolarization in hippocampus by inhibiting calcium-induced calcium release.
    G E Torres, C L Arfken and R Andrade
    Molecular Pharmacology November 1996, 50 (5) 1316-1322;
  • You have access
    Identification of competitive antagonists of the P2Y1 receptor.
    J L Boyer, T Romero-Avila, J B Schachter and T K Harden
    Molecular Pharmacology November 1996, 50 (5) 1323-1329;
  • You have access
    Subunit composition is a major determinant in high affinity binding of a Ca2+ channel blocker.
    H Suh-Kim, X Wei and L Birnbaumer
    Molecular Pharmacology November 1996, 50 (5) 1330-1337;
  • You have access
    Mutagenesis of residues adjacent to transmembrane prolines alters D1 dopamine receptor binding and signal transduction.
    W Cho, L P Taylor and H Akil
    Molecular Pharmacology November 1996, 50 (5) 1338-1345;
  • You have access
    Bombesin-like peptide receptor subtypes promote mitogenesis, which requires persistent receptor signaling.
    R I Feldman, M F Bartholdi and J M Wu
    Molecular Pharmacology November 1996, 50 (5) 1346-1354;
  • You have access
    Discovery of high affinity bombesin receptor subtype 3 agonists.
    J M Wu, D E Nitecki, S Biancalana and R I Feldman
    Molecular Pharmacology November 1996, 50 (5) 1355-1363;
  • You have access
    Pharmacology of the human gamma-aminobutyric acidA receptor alpha 4 subunit expressed in Xenopus laevis oocytes.
    E R Whittemore, W Yang, J A Drewe and R M Woodward
    Molecular Pharmacology November 1996, 50 (5) 1364-1375;
  • You have access
    Coupling efficiencies of human alpha 1-adrenergic receptor subtypes: titration of receptor density and responsiveness with inducible and repressible expression vectors.
    T L Theroux, T A Esbenshade, R D Peavy and K P Minneman
    Molecular Pharmacology November 1996, 50 (5) 1376-1387;
  • You have access
    Distinct effects of mutations in transmembrane segment IVS6 on block of L-type calcium channels by structurally similar phenylalkylamines.
    B D Johnson, G H Hockerman, T Scheuer and W A Catterall
    Molecular Pharmacology November 1996, 50 (5) 1388-1400;
  • You have access
    Dose-response relations for unnatural amino acids at the agonist binding site of the nicotinic acetylcholine receptor: tests with novel side chains and with several agonists.
    P C Kearney, M W Nowak, W Zhong, S K Silverman, H A Lester and D A Dougherty
    Molecular Pharmacology November 1996, 50 (5) 1401-1412;
  • You have access
    A single residue, Lys108, of the delta-opioid receptor prevents the mu-opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor.
    M Minami, T Nakagawa, T Seki, T Onogi, Y Aoki, Y Katao, S Katsumata and M Satoh
    Molecular Pharmacology November 1996, 50 (5) 1413-1422;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 50, Issue 5
1 Nov 1996
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics